1. Home
  2. SLP vs CERS Comparison

SLP vs CERS Comparison

Compare SLP & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Simulations Plus Inc.

SLP

Simulations Plus Inc.

HOLD

Current Price

$19.18

Market Cap

322.4M

Sector

Technology

ML Signal

HOLD

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$2.06

Market Cap

276.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLP
CERS
Founded
1996
1991
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
322.4M
276.0M
IPO Year
1997
1997

Fundamental Metrics

Financial Performance
Metric
SLP
CERS
Price
$19.18
$2.06
Analyst Decision
Buy
Buy
Analyst Count
7
1
Target Price
$27.25
$4.00
AVG Volume (30 Days)
336.7K
1.6M
Earning Date
01-08-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$79,179,000.00
$199,191,000.00
Revenue This Year
$2.02
$25.31
Revenue Next Year
$6.92
$9.50
P/E Ratio
N/A
N/A
Revenue Growth
13.09
13.03
52 Week Low
$12.39
$1.12
52 Week High
$37.67
$2.26

Technical Indicators

Market Signals
Indicator
SLP
CERS
Relative Strength Index (RSI) 56.71 57.06
Support Level $17.74 $2.00
Resistance Level $19.62 $2.21
Average True Range (ATR) 0.72 0.15
MACD -0.09 -0.01
Stochastic Oscillator 53.23 55.56

Price Performance

Historical Comparison
SLP
CERS

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: